Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy


A Randomized, Double-Blinded, Placebo-Controlled Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy




The purpose of this study is to determine if an investigational cell therapy called Cvac can help prevent EOC from returning when administered to patients who are in complete remission after surgical removal of their tumor followed by standard first-line chemotherapy. Following surgery and study randomization, patients will undergo leukapheresis for manufacture of the study agent and then begin first-line chemotherapy. After completion of chemotherapy and confirmation of complete remission, patients will enter the treatment phase of the study.

Study Status: Active, not recruiting


Condition Intervention Phase
Epithelial Ovarian Cancer Biological: Placebo Study Agent
Biological: Cvac
Phase 2/Phase 3

Verified by Prima BioMed Ltd October, 2013

Sponsored by: Prima BioMed Ltd
Information provided by: Prima BioMed Ltd identifier: NCT01521143

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site